Share price · KMDA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when KMDA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026+5.1%
- Day beforeKamada: REPORT OF FOREIGN PRIVATE ISSUER
- 5 Oct 2026-3.7%
- 13 Aug 2026+5.5%
- Day beforeKamada: REPORT OF FOREIGN PRIVATE ISSUER
- 13 May 2026-6.8%
Nothing announced by KMDA that day or the session before.
- 17 Feb 2026+6.8%
Nothing announced by KMDA that day or the session before.
- 26 Jan 2026+8.1%
Nothing announced by KMDA that day or the session before.
- 20 Jan 2026-4.4%
Nothing announced by KMDA that day or the session before.
- 15 Jan 2026+3.3%
Nothing announced by KMDA that day or the session before.
Share of unusual movement by asset
For each asset, the share of KMDA's own-move activity since 14 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 16% |
| Sessions with no dated event | — | 84% |
No dated announcements about its assets since 14 Oct 2025.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | HBsAgProtein / enzyme therapeutic | Chronic Hepatitis B |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (12)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | $47M | $2.6M | $72M | —$10M operating cash flow | report ↗ |
View 11 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q2 | $45M | $3.2M | $66M | —$8.0M operating cash flow | report ↗ |
| 2025-Q1 | $44M | $4.3M | $76M | —-$0.5M operating cash flow | report ↗ |
| 2024-Q3 | $42M | $3.4M | $72M | —$22M operating cash flow | report ↗ |
| 2024-Q2 | $42M | $4.8M | $57M | —$14M operating cash flow | report ↗ |
| 2024-Q1 | <$0.1M | $0 | $0.1M | —$0 operating cash flow | report ↗ |
| 2023-Q3 | <$0.1M | $0 | $0.1M | —$0 operating cash flow | report ↗ |
| 2023-Q2 | $37M | $4.3M | $22M | —$1.8M operating cash flow | report ↗ |
| 2023-Q1 | $31M | $3.2M | $27M | $1.8M-$2.9M operating cash flow | report ↗ |
| 2022-Q3 | $32M | $3.1M | $31M | —$5.5M operating cash flow | report ↗ |
| 2022-Q2 | $24M | $2.6M | $30M | $3.9M$11M operating cash flow | report ↗ |
| 2022-Q1 | $28M | $4.4M | $22M | $1.8M$5.5M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $180M | $13M | $75M | —$25M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 4 sales ($1.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-14 | Tsur David · director | Open-market sale | 22,827 | $8.18 | $187K | Form 4 |
| 2026-09-14 | Livneh Nir · VP, General Counsel | Option exercise | 10,000 | $5.37 | $54K | Form 4 |
| 2026-09-14 | Brenner Yael · VP Quality | Option exercise | 5,000 | $5.93 | $30K | Form 4 |
| 2026-09-14 | Livneh Nir · VP, General Counsel | Tax withholding | 3,459 | $8.35 | $29K | Form 4 |
| 2026-09-14 | Brenner Yael · VP Quality | Tax withholding | 1,371 | $8.36 | $11K | Form 4 |
| 2026-09-14 | Livneh Nir · VP, General Counsel | Option exercise (derivative) | 10,000 | — | — | Form 4 |
| 2026-09-14 | Brenner Yael · VP Quality | Option exercise | 5,000 | $5.93 | $30K | Form 4 |
| 2026-09-14 | Brenner Yael · VP Quality | Tax withholding | 1,371 | $8.36 | $11K | Form 4 |